東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

Using Chemoproteomic and Metabolomic...

Hunerdosse, Devon.

Linked to FindBook

Google Book

Amazon

博客來

Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation./
Author:	Hunerdosse, Devon.
Description:	90 p.
Notes:	Source: Dissertation Abstracts International, Volume: 77-01(E), Section: B.
Contained By:	Dissertation Abstracts International77-01B(E).
Subject:	Neurosciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3720574
ISBN:	9781339016047

Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation.
Hunerdosse, Devon.

Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation. - 90 p.

Source: Dissertation Abstracts International, Volume: 77-01(E), Section: B.

Thesis (Ph.D.)--University of California, Berkeley, 2015.

There are an increasing number of human pathologies that have been associated with altered metabolism, including obesity, diabetes, cancer, atherosclerosis, and neurodegenerative diseases. Most attention on metabolism has been focused on well-understood metabolic pathways and has largely ignored most of the biochemical pathways that operate in physiological and pathophysiological settings. This is, in part, because of the vast landscape of uncharacterized and yet-undiscovered enzymes and metabolites that operate in metabolism. One technology that has arisen to address this challenge is activity-based protein profiling (ABPP). ABPP uses activity-based chemical probes to broadly assess the functional states of characterized and uncharacterized enzymes alike across entire enzyme classes. ABPP, when coupled with inhibitor discovery platforms and functional metabolomic technologies has led to discoveries that increase our definition of known biochemical pathways to expand our knowledge of metabolism in human health and disease.

ISBN: 9781339016047Subjects--Topical Terms:

588700
Neurosciences.

Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation.
LDR:03478nmm a2200325 4500 001 2077564
005 20161114130327.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781339016047
035 $a (MiAaPQ)AAI3720574
035 $a AAI3720574
040 $a MiAaPQ $c MiAaPQ
100 1 $a Hunerdosse, Devon. $3 3193075
245 1 0 $a Using Chemoproteomic and Metabolomic Platforms to Identify Nodal Metabolic Pathways Important to Inflammation.
300 $a 90 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-01(E), Section: B.
500 $a Adviser: Daniel Nomura.
502 $a Thesis (Ph.D.)--University of California, Berkeley, 2015.
520 $a There are an increasing number of human pathologies that have been associated with altered metabolism, including obesity, diabetes, cancer, atherosclerosis, and neurodegenerative diseases. Most attention on metabolism has been focused on well-understood metabolic pathways and has largely ignored most of the biochemical pathways that operate in physiological and pathophysiological settings. This is, in part, because of the vast landscape of uncharacterized and yet-undiscovered enzymes and metabolites that operate in metabolism. One technology that has arisen to address this challenge is activity-based protein profiling (ABPP). ABPP uses activity-based chemical probes to broadly assess the functional states of characterized and uncharacterized enzymes alike across entire enzyme classes. ABPP, when coupled with inhibitor discovery platforms and functional metabolomic technologies has led to discoveries that increase our definition of known biochemical pathways to expand our knowledge of metabolism in human health and disease.
520 $a Being able to identify key nodal metabolic pathways will undoubtedly lead to new therapeutic strategies for combating diseases associated with metabolism. We are particularly interested in studying inflammatory metabolism, because chronic, low-grade inflammation is increasingly associated with many human pathologies. Although there are several successfully marketed small molecule anti-inflammatory drugs such as cyclooxygenase inhibitors and glucocorticoids, many of these compounds are also associated with various adverse cardiovascular or immunosuppressive effects. Thus, identifying novel anti-inflammatory small molecules and their biological targets is critical for developing safer and more effective treatment strategies for inflammatory diseases.
520 $a We conducted a chemical genetics screen to identify small molecules that suppress the release of the pro-inflammatory cytokine TNFalpha from stimulated macrophages. We have used an enzyme class-directed chemical library for our screening efforts to facilitate subsequent target identification using ABPP. Using this strategy, we have found that KIAA1363 is a novel target for lowering certain pro-inflammatory cytokines through affecting key ether lipid metabolism pathways. This study highlights the application of combining chemical genetics with chemoproteomic and metabolomic approaches toward identifying and characterizing anti-inflammatory small molecules and their targets.
590 $a School code: 0028.
650 4 $a Neurosciences. $3 588700
650 4 $a Cellular biology. $3 3172791
650 4 $a Molecular biology. $3 517296
650 4 $a Oncology. $3 751006
690 $a 0317
690 $a 0379
690 $a 0307
690 $a 0992
710 2 $a University of California, Berkeley. $b Endocrinology. $3 3193076
773 0 $t Dissertation Abstracts International $g 77-01B(E).
790 $a 0028
791 $a Ph.D.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3720574